Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company developing personalized dendritic-cell immunotherapies for cancer. Its lead candidate, DCVax-L, has completed a Phase 3 trial in glioblastoma (GBM), an aggressive brain cancer, and is under regulatory review in the United Kingdom. The question facing investors is whether the shares — trading near $0.17 — can climb to the $1.00 price objective that is most commonly discussed publicly.
Unlike widely followed large caps, NWBO has almost no sell-side coverage. Financial data providers list only one active analyst, and some trackers show none. The $1.00 objective comes from First Berlin Equity Research, where analyst Christian Orquera initiated coverage with a Buy rating and a $1.00 price target in March 2026 and has reiterated it through mid-2026. Because a single note cannot form a meaningful "analyst consensus," the $1.00 figure is presented here as a publicly discussed research objective rather than an average analyst price target.
First Berlin bases the target on a sum-of-the-parts (SOTP) valuation of DCVax-L, arguing the therapy could be the first meaningful advance in GBM treatment in roughly two decades. The firm's thesis assumes a positive MHRA decision, pricing and reimbursement talks, and a first UK commercial launch in 2027, with later filings in the US, Canada, and Europe. It is important to recognize that this is one firm's modeled valuation, not a forecast of near-term market behavior.
Shares of NWBO trade near $0.17, with a market capitalization of roughly $290 million and more than 1.7 billion shares outstanding after sustained dilution. Reaching $1.00 from approximately $0.17 implies an upside of about 490%. That is a very large required move, comparable to a repricing of the company's entire risk profile rather than an incremental re-rating.
The path would likely run through a binary regulatory event. A favorable MHRA decision on the Marketing Authorisation Application (MAA) for DCVax-L would, in the bull case, unlock negotiations with the National Institute for Health and Care Excellence (NICE) and a reimbursed UK launch. From there, expansion into additional jurisdictions would be needed to justify a materially higher valuation. The company is expanding manufacturing capacity at its Sawston facility in the UK and has added experienced commercial leadership, steps consistent with preparing for a potential launch.
NWBO trades near the bottom of a 52-week range of roughly $0.14 to $0.34. The stock has retraced much of its early-2026 strength and now sits close to support near the $0.14 low. Resistance appears concentrated around $0.20 to $0.21 — an area tied to a recent warrant price — with the prior high near $0.34 representing a more distant ceiling. The $1.00 target is far above any established trading range and has no nearby technical anchor.
First Berlin's target carries a stated 12-month horizon, reflecting a research window rather than a guarantee. The most consequential upcoming items are the MHRA decision on DCVax-L, any subsequent NICE pricing and reimbursement developments, quarterly results and cash position, financing and share-count updates, and manufacturing-readiness announcements. Investors should also watch for additional regulatory filings in other jurisdictions, which would signal the start of a broader commercial rollout.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For a volatile, thinly covered name like NWBO, such signal-based tools can offer an additional, data-driven lens alongside fundamental research.
The $1.00 objective for NWBO is a single analyst's modeled valuation, not a broad consensus, and it would require a roughly 490% advance from current levels. The bull case is concentrated in one binary event — a favorable MHRA decision on DCVax-L — reinforced by new survival data and commercial preparations. The bear case rests on going-concern uncertainty, persistent dilution, and the possibility that approval or reimbursement falls short of expectations. Given the thinness of coverage, investors should treat the $1.00 figure cautiously and focus on the regulatory, financing, and commercialization milestones that will ultimately determine whether such a re-rating is achievable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.